Pfizer
Smita Mukherjee, PhD, MBA, serves as the HCP Director for Hemophilia Portfolio Marketing at Pfizer, focusing on rare diseases since December 2022. Prior roles include leadership in the US marketing launch for Marstacimab at Pfizer and positions at Bristol Myers Squibb as Associate Director for Multiple Myeloma marketing, and Novartis Oncology as Senior Product Manager and MBA Summer Associate in Breast Cancer Marketing. Additionally, Smita has experience as a Commercialization and Strategy Lead at Detect and as a Fellow at Harlem Biospace. Academic credentials include an MBA from The Wharton School, a PhD in Biophysical Chemistry from the University of Pennsylvania, and a BA in Biochemistry from Hood College.
This person is not in any teams
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.